Enliven Therapeutics (ELVN) shares are in focus after the company reported encouraging initial Phase 1b data for ELVN-001 in ...
In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...
The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...
Enliven Therapeutics' stock rose after early trial results showed strong responses and good safety for its leukemia drug, ...
Enliven Therapeutics, Inc. (Enliven or the Company) , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced positive ...
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market ...
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the co ...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback